Bill Haynes
Scientific Corporate Vice President, Research & Development, Novo Nordisk
Bill Haynes is a Scientific CVP for Cardiovascular disease, focusing on driving a competitive and recognized level of innovation and scientific rigor to the research activities at Novo Nordisk.
Bill is a physician-scientist with more than 25 years of experience in academic-industry translational research in cardiometabolic disease, supported by Wellcome, National Institute of Health (NIH), Juvenile Diabetes Research Foundation and Swedish Foundation for Strategic Research. Bill trained in medicine and translational research in the UK and was a Professor of Endocrinology and Cardiovascular diseases at the University of Iowa. In 2013, Bill transitioned to the pharma industry, working in discovery research and translational medicine at Novartis and AstraZeneca, and driving novel targets in diabetes, non-alcoholic steatohepatitis (NASH), cardiovascular (CV) disease and obesity towards clinical development. He has led multiple high high-profile collaborations with academic institutions including the University of Oxford, Harvard, INSERM and the Karolinska Institute.
Bill is a fellow of the American Heart Association and The Obesity Society and an elected member of the American Society of Clinical Investigation.